Logo
x

Search

Subscribe Now

Karyopharm

Karyopharm and Menarini Receive MHRA’s Marketing Authorization of Nexpovio (selinexor) for the Treatment of Multiple Myeloma

Karyopharm and Menarini Receive MHRA’s Marketing Authorization of Nexpovio (selinexor) for the Treatment of Multiple Myeloma

  • February 22, 2023
Karyopharm and Menarini's Nexpovio (selinexor) Receive EC's Marketing Authorisation for the Treatment of Multiple Myeloma

Karyopharm and Menarini's Nexpovio (selinexor) Receive EC's Marketing Authorisation for the Treatment of Multiple Myeloma

  • July 22, 2022
Karyopharm Reports Results of Selinexor in P-III (SIENDO) Study for the Treatment of Advanced or Recurrent Endometrial Cancer.

Karyopharm Reports Results of Selinexor in P-III (SIENDO) Study for the Treatment of Advanced or Recurrent Endometrial Cancer.

  • February 9, 2022
Karyopharm’s Eltanexor Receives the US FDA’s Orphan Drug Designation for the Treatment of Myelodysplastic Syndromes.

Karyopharm’s Eltanexor Receives the US FDA’s Orphan Drug Designation for the Treatment of Myelodysplastic Syndromes.

  • January 25, 2022
Karyopharm Signs an Exclusive License Agreement with Menarini to Commercialize Nexpovio (selinexor) for Oncology

Karyopharm Signs an Exclusive License Agreement with Menarini to Commercialize Nexpovio (selinexor) for Oncology

  • December 22, 2021
Insights+: Key Deals of J.P. Morgan Healthcare Conference 2020

Insights+: Key Deals of J.P. Morgan Healthcare Conference 2020

  • February 7, 2020
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.